INSIGHTS ON CLINICAL TRIAL DESIGN

• Mental Health: 5 Facts About Psychedelics

  As mental health issues surge globally, especially following the COVID-19 pandemic, renewed interest in psychedelic drugs is driving research into their potential therapeutic uses.

• Reduction Of Screen Failures In A Biomarker

  Targeted prescreening for biomarker and cognitive criteria cut screen failures in a complex Alzheimer’s trial, speeding enrollment and improving site efficiency while maintaining strict eligibility.

   

• Pay-By-Procedure Or Pay-By-Visit: Which Model Fits Your Trial?

  Site payment models shape trial cost and execution. Compare visit‑based simplicity vs procedure‑level precision to see when flexibility and savings beat complexity — or when predictability wins.

   

• The Pharmacy Advantage In Direct-To-Patient Clinical Supply

  Understand state pharmacy regulations, prescription requirements, and operational considerations for shipping clinical supplies directly from pharmacies to patients' homes in decentralized trial models.

• Digital Transformation As A Foundation For Modern Chronic Disease Trials

  6/16/2026

  Site-centric chronic trials cause patient burden. Learn how wearables and a decentralized model can shift research to continuous data capture, removing travel barriers to improve retention and disease tracking.

• Mergers And Acquisitions: How Institutional Knowledge Protecting Value

  5/27/2026

  M&A transitions can either preserve momentum or create costly setbacks. Learn how protecting institutional knowledge helps sponsors reduce risk, maintain continuity, and accelerate development.

• Multi-Regional Clinical Trials: The Latest Guidance From FDA

  3/12/2025

  Conducting multi-regional clinical trials (MRCTs) is essential for accelerating oncology drug development and ensuring broader patient access. However, differences across regions can impact findings.

• Reducing The Burden Of Patient Retention And Improving Continuity

  1/6/2026

  Immunology trials often place a sustained burden on participants. However, integrating Home Trial Support (HTS) into a Phase 3 immunology trial can help improve the overall study experience.

• Developing Community-Based And Trial-Naïve Sites: The Real ROI

  9/9/2025

  Trial-naïve sites, when supported with infrastructure, training, and network integration, represent a critical yet underused opportunity to expand patient access and accelerate recruitment.